Skip to content
The Nexus
DossierENTITY

respiratory syncytial virus

Coverage of respiratory syncytial virus in the Nexus archive.

Earliest in view: Apr 9 · 22:27 UTCMost recent: Jul 20 · 18:45 UTC
Co-mentioned in this coverage
Clesrovimabtopic1Enflonsiatopic1MedPage Todayorganization1infants at increased risk for severe diseasetopic1randomized clinical trialtopic1American College of Obstetricians & Gynecologistsorganization1Centers for Disease Control and Preventionorganization1flu shottopic1COVID-19 shottopic1tetanus, diphtheria and pertussis (Tdap)topic1The Hillorganization1Statesplace1
Recent coverage
  • HEALTHJul 20 · 18:45 UTCMEDPAGE TODAY
    Second Season of Clesrovimab for RSV Well Tolerated in High-Risk Kids

    The long-acting monoclonal antibody clesrovimab (Enflonsia) was well tolerated in high-risk infants during two RSV seasons, according to a randomized clinical trial. The drug is used for RSV prevention in infants at increased risk for severe disease.

  • HEALTHJun 10 · 18:17 UTCTHE HILL
    Leading OB-GYN group issues vaccine recommendations, breaks with CDC

    The American College of Obstetricians & Gynecologists (ACOG) released a maternal vaccine schedule that diverges from CDC guidance, recommending four vaccines during pregnancy: flu, COVID-19, Tdap, and respiratory syncytial virus (RSV) protection. This marks the first time ACOG's recommendations conflict with CDC's stance on maternal immunization.

  • HEALTHApr 9 · 22:27 UTCTHE HILL
    RSV season runs into spring

    An unusually late RSV season is extending into spring, prompting states to expand eligibility for preventive measures in children. Experts advise parents to remain vigilant about protective actions despite the delayed season.